|
Sen. Melinda Bush
Filed: 1/8/2021
| | 10100HB2488sam003 | | LRB101 07727 BMS 74688 a |
|
|
1 | | AMENDMENT TO HOUSE BILL 2488
|
2 | | AMENDMENT NO. ______. Amend House Bill 2488 by replacing |
3 | | everything after the enacting clause with the following:
|
4 | | "Section 5. The Illinois Controlled Substances Act is |
5 | | amended by changing Section 102 and by adding Section 220 as |
6 | | follows: |
7 | | (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) |
8 | | Sec. 102. Definitions. As used in this Act, unless the |
9 | | context
otherwise requires:
|
10 | | (a) "Addict" means any person who habitually uses any drug, |
11 | | chemical,
substance or dangerous drug other than alcohol so as |
12 | | to endanger the public
morals, health, safety or welfare or who |
13 | | is so far addicted to the use of a
dangerous drug or controlled |
14 | | substance other than alcohol as to have lost
the power of self |
15 | | control with reference to his or her addiction.
|
16 | | (b) "Administer" means the direct application of a |
|
| | 10100HB2488sam003 | - 2 - | LRB101 07727 BMS 74688 a |
|
|
1 | | controlled
substance, whether by injection, inhalation, |
2 | | ingestion, or any other
means, to the body of a patient, |
3 | | research subject, or animal (as
defined by the Humane |
4 | | Euthanasia in Animal Shelters Act) by:
|
5 | | (1) a practitioner (or, in his or her presence, by his |
6 | | or her authorized agent),
|
7 | | (2) the patient or research subject pursuant to an |
8 | | order, or
|
9 | | (3) a euthanasia technician as defined by the Humane |
10 | | Euthanasia in
Animal Shelters Act.
|
11 | | (c) "Agent" means an authorized person who acts on behalf |
12 | | of or at
the direction of a manufacturer, distributor, |
13 | | dispenser, prescriber, or practitioner. It does not
include a |
14 | | common or contract carrier, public warehouseman or employee of
|
15 | | the carrier or warehouseman.
|
16 | | (c-1) "Anabolic Steroids" means any drug or hormonal |
17 | | substance,
chemically and pharmacologically related to |
18 | | testosterone (other than
estrogens, progestins, |
19 | | corticosteroids, and dehydroepiandrosterone),
and includes:
|
20 | | (i) 3[beta],17-dihydroxy-5a-androstane, |
21 | | (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, |
22 | | (iii) 5[alpha]-androstan-3,17-dione, |
23 | | (iv) 1-androstenediol (3[beta], |
24 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), |
25 | | (v) 1-androstenediol (3[alpha], |
26 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), |
|
| | 10100HB2488sam003 | - 3 - | LRB101 07727 BMS 74688 a |
|
|
1 | | (vi) 4-androstenediol |
2 | | (3[beta],17[beta]-dihydroxy-androst-4-ene), |
3 | | (vii) 5-androstenediol |
4 | | (3[beta],17[beta]-dihydroxy-androst-5-ene), |
5 | | (viii) 1-androstenedione |
6 | | ([5alpha]-androst-1-en-3,17-dione), |
7 | | (ix) 4-androstenedione |
8 | | (androst-4-en-3,17-dione), |
9 | | (x) 5-androstenedione |
10 | | (androst-5-en-3,17-dione), |
11 | | (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- |
12 | | hydroxyandrost-4-en-3-one), |
13 | | (xii) boldenone (17[beta]-hydroxyandrost- |
14 | | 1,4,-diene-3-one), |
15 | | (xiii) boldione (androsta-1,4- |
16 | | diene-3,17-dione), |
17 | | (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 |
18 | | [beta]-hydroxyandrost-4-en-3-one), |
19 | | (xv) clostebol (4-chloro-17[beta]- |
20 | | hydroxyandrost-4-en-3-one), |
21 | | (xvi) dehydrochloromethyltestosterone (4-chloro- |
22 | | 17[beta]-hydroxy-17[alpha]-methyl- |
23 | | androst-1,4-dien-3-one), |
24 | | (xvii) desoxymethyltestosterone |
25 | | (17[alpha]-methyl-5[alpha] |
26 | | -androst-2-en-17[beta]-ol)(a.k.a., madol), |
|
| | 10100HB2488sam003 | - 4 - | LRB101 07727 BMS 74688 a |
|
|
1 | | (xviii) [delta]1-dihydrotestosterone (a.k.a. |
2 | | '1-testosterone') (17[beta]-hydroxy- |
3 | | 5[alpha]-androst-1-en-3-one), |
4 | | (xix) 4-dihydrotestosterone (17[beta]-hydroxy- |
5 | | androstan-3-one), |
6 | | (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- |
7 | | 5[alpha]-androstan-3-one), |
8 | | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- |
9 | | hydroxyestr-4-ene), |
10 | | (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- |
11 | | 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), |
12 | | (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], |
13 | | 17[beta]-dihydroxyandrost-1,4-dien-3-one), |
14 | | (xxiv) furazabol (17[alpha]-methyl-17[beta]- |
15 | | hydroxyandrostano[2,3-c]-furazan), |
16 | | (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, |
17 | | (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- |
18 | | androst-4-en-3-one), |
19 | | (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- |
20 | | dihydroxy-estr-4-en-3-one), |
21 | | (xxviii) mestanolone (17[alpha]-methyl-17[beta]- |
22 | | hydroxy-5-androstan-3-one), |
23 | | (xxix) mesterolone (1amethyl-17[beta]-hydroxy- |
24 | | [5a]-androstan-3-one), |
25 | | (xxx) methandienone (17[alpha]-methyl-17[beta]- |
26 | | hydroxyandrost-1,4-dien-3-one), |
|
| | 10100HB2488sam003 | - 5 - | LRB101 07727 BMS 74688 a |
|
|
1 | | (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- |
2 | | dihydroxyandrost-5-ene), |
3 | | (xxxii) methenolone (1-methyl-17[beta]-hydroxy- |
4 | | 5[alpha]-androst-1-en-3-one), |
5 | | (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- |
6 | | dihydroxy-5a-androstane, |
7 | | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy |
8 | | -5a-androstane, |
9 | | (xxxv) 17[alpha]-methyl-3[beta],17[beta]- |
10 | | dihydroxyandrost-4-ene), |
11 | | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- |
12 | | methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), |
13 | | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- |
14 | | hydroxyestra-4,9(10)-dien-3-one), |
15 | | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- |
16 | | hydroxyestra-4,9-11-trien-3-one), |
17 | | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- |
18 | | hydroxyandrost-4-en-3-one), |
19 | | (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- |
20 | | hydroxyestr-4-en-3-one), |
21 | | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone |
22 | | (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- |
23 | | androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- |
24 | | 1-testosterone'), |
25 | | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), |
26 | | (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- |
|
| | 10100HB2488sam003 | - 6 - | LRB101 07727 BMS 74688 a |
|
|
1 | | dihydroxyestr-4-ene), |
2 | | (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- |
3 | | dihydroxyestr-4-ene), |
4 | | (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- |
5 | | dihydroxyestr-5-ene), |
6 | | (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- |
7 | | dihydroxyestr-5-ene), |
8 | | (xlvii) 19-nor-4,9(10)-androstadienedione |
9 | | (estra-4,9(10)-diene-3,17-dione), |
10 | | (xlviii) 19-nor-4-androstenedione (estr-4- |
11 | | en-3,17-dione), |
12 | | (xlix) 19-nor-5-androstenedione (estr-5- |
13 | | en-3,17-dione), |
14 | | (l) norbolethone (13[beta], 17a-diethyl-17[beta]- |
15 | | hydroxygon-4-en-3-one), |
16 | | (li) norclostebol (4-chloro-17[beta]- |
17 | | hydroxyestr-4-en-3-one), |
18 | | (lii) norethandrolone (17[alpha]-ethyl-17[beta]- |
19 | | hydroxyestr-4-en-3-one), |
20 | | (liii) normethandrolone (17[alpha]-methyl-17[beta]- |
21 | | hydroxyestr-4-en-3-one), |
22 | | (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- |
23 | | 2-oxa-5[alpha]-androstan-3-one), |
24 | | (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- |
25 | | dihydroxyandrost-4-en-3-one), |
26 | | (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- |
|
| | 10100HB2488sam003 | - 7 - | LRB101 07727 BMS 74688 a |
|
|
1 | | 17[beta]-hydroxy-(5[alpha]-androstan-3-one), |
2 | | (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- |
3 | | (5[alpha]-androst-2-eno[3,2-c]-pyrazole), |
4 | | (lviii) stenbolone (17[beta]-hydroxy-2-methyl- |
5 | | (5[alpha]-androst-1-en-3-one), |
6 | | (lix) testolactone (13-hydroxy-3-oxo-13,17- |
7 | | secoandrosta-1,4-dien-17-oic |
8 | | acid lactone), |
9 | | (lx) testosterone (17[beta]-hydroxyandrost- |
10 | | 4-en-3-one), |
11 | | (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- |
12 | | diethyl-17[beta]-hydroxygon- |
13 | | 4,9,11-trien-3-one), |
14 | | (lxii) trenbolone (17[beta]-hydroxyestr-4,9, |
15 | | 11-trien-3-one).
|
16 | | Any person who is otherwise lawfully in possession of an |
17 | | anabolic
steroid, or who otherwise lawfully manufactures, |
18 | | distributes, dispenses,
delivers, or possesses with intent to |
19 | | deliver an anabolic steroid, which
anabolic steroid is |
20 | | expressly intended for and lawfully allowed to be
administered |
21 | | through implants to livestock or other nonhuman species, and
|
22 | | which is approved by the Secretary of Health and Human Services |
23 | | for such
administration, and which the person intends to |
24 | | administer or have
administered through such implants, shall |
25 | | not be considered to be in
unauthorized possession or to |
26 | | unlawfully manufacture, distribute, dispense,
deliver, or |
|
| | 10100HB2488sam003 | - 8 - | LRB101 07727 BMS 74688 a |
|
|
1 | | possess with intent to deliver such anabolic steroid for
|
2 | | purposes of this Act.
|
3 | | (d) "Administration" means the Drug Enforcement |
4 | | Administration,
United States Department of Justice, or its |
5 | | successor agency.
|
6 | | (d-5) "Clinical Director, Prescription Monitoring Program" |
7 | | means a Department of Human Services administrative employee |
8 | | licensed to either prescribe or dispense controlled substances |
9 | | who shall run the clinical aspects of the Department of Human |
10 | | Services Prescription Monitoring Program and its Prescription |
11 | | Information Library. |
12 | | (d-10) "Compounding" means the preparation and mixing of |
13 | | components, excluding flavorings, (1) as the result of a |
14 | | prescriber's prescription drug order or initiative based on the |
15 | | prescriber-patient-pharmacist relationship in the course of |
16 | | professional practice or (2) for the purpose of, or incident |
17 | | to, research, teaching, or chemical analysis and not for sale |
18 | | or dispensing. "Compounding" includes the preparation of drugs |
19 | | or devices in anticipation of receiving prescription drug |
20 | | orders based on routine, regularly observed dispensing |
21 | | patterns. Commercially available products may be compounded |
22 | | for dispensing to individual patients only if both of the |
23 | | following conditions are met: (i) the commercial product is not |
24 | | reasonably available from normal distribution channels in a |
25 | | timely manner to meet the patient's needs and (ii) the |
26 | | prescribing practitioner has requested that the drug be |
|
| | 10100HB2488sam003 | - 9 - | LRB101 07727 BMS 74688 a |
|
|
1 | | compounded. |
2 | | (e) "Control" means to add a drug or other substance, or |
3 | | immediate
precursor, to a Schedule whether by
transfer from |
4 | | another Schedule or otherwise.
|
5 | | (f) "Controlled Substance" means (i) a drug, substance, |
6 | | immediate
precursor, or synthetic drug in the Schedules of |
7 | | Article II of this Act or (ii) a drug or other substance, or |
8 | | immediate precursor, designated as a controlled substance by |
9 | | the Department through administrative rule. The term does not |
10 | | include distilled spirits, wine, malt beverages, or tobacco, as |
11 | | those terms are
defined or used in the Liquor Control Act of |
12 | | 1934 and the Tobacco Products Tax
Act of 1995.
|
13 | | (f-5) "Controlled substance analog" means a substance: |
14 | | (1) the chemical structure of which is substantially |
15 | | similar to the chemical structure of a controlled substance |
16 | | in Schedule I or II; |
17 | | (2) which has a stimulant, depressant, or |
18 | | hallucinogenic effect on the central nervous system that is |
19 | | substantially similar to or greater than the stimulant, |
20 | | depressant, or hallucinogenic effect on the central |
21 | | nervous system of a controlled substance in Schedule I or |
22 | | II; or |
23 | | (3) with respect to a particular person, which such |
24 | | person represents or intends to have a stimulant, |
25 | | depressant, or hallucinogenic effect on the central |
26 | | nervous system that is substantially similar to or greater |
|
| | 10100HB2488sam003 | - 10 - | LRB101 07727 BMS 74688 a |
|
|
1 | | than the stimulant, depressant, or hallucinogenic effect |
2 | | on the central nervous system of a controlled substance in |
3 | | Schedule I or II. |
4 | | (g) "Counterfeit substance" means a controlled substance, |
5 | | which, or
the container or labeling of which, without |
6 | | authorization bears the
trademark, trade name, or other |
7 | | identifying mark, imprint, number or
device, or any likeness |
8 | | thereof, of a manufacturer, distributor, or
dispenser other |
9 | | than the person who in fact manufactured, distributed,
or |
10 | | dispensed the substance.
|
11 | | (h) "Deliver" or "delivery" means the actual, constructive |
12 | | or
attempted transfer of possession of a controlled substance, |
13 | | with or
without consideration, whether or not there is an |
14 | | agency relationship.
|
15 | | (i) "Department" means the Illinois Department of Human |
16 | | Services (as
successor to the Department of Alcoholism and |
17 | | Substance Abuse) or its successor agency.
|
18 | | (j) (Blank).
|
19 | | (k) "Department of Corrections" means the Department of |
20 | | Corrections
of the State of Illinois or its successor agency.
|
21 | | (l) "Department of Financial and Professional Regulation" |
22 | | means the Department
of Financial and Professional Regulation |
23 | | of the State of Illinois or its successor agency.
|
24 | | (m) "Depressant" means any drug that (i) causes an overall |
25 | | depression of central nervous system functions, (ii) causes |
26 | | impaired consciousness and awareness, and (iii) can be |
|
| | 10100HB2488sam003 | - 11 - | LRB101 07727 BMS 74688 a |
|
|
1 | | habit-forming or lead to a substance abuse problem, including |
2 | | but not limited to alcohol, cannabis and its active principles |
3 | | and their analogs, benzodiazepines and their analogs, |
4 | | barbiturates and their analogs, opioids (natural and |
5 | | synthetic) and their analogs, and chloral hydrate and similar |
6 | | sedative hypnotics.
|
7 | | (n) (Blank).
|
8 | | (o) "Director" means the Director of the Illinois State |
9 | | Police or his or her designated agents.
|
10 | | (p) "Dispense" means to deliver a controlled substance to |
11 | | an
ultimate user or research subject by or pursuant to the |
12 | | lawful order of
a prescriber, including the prescribing, |
13 | | administering, packaging,
labeling, or compounding necessary |
14 | | to prepare the substance for that
delivery.
|
15 | | (q) "Dispenser" means a practitioner who dispenses.
|
16 | | (r) "Distribute" means to deliver, other than by |
17 | | administering or
dispensing, a controlled substance.
|
18 | | (s) "Distributor" means a person who distributes.
|
19 | | (t) "Drug" means (1) substances recognized as drugs in the |
20 | | official
United States Pharmacopoeia, Official Homeopathic |
21 | | Pharmacopoeia of the
United States, or official National |
22 | | Formulary, or any supplement to any
of them; (2) substances |
23 | | intended for use in diagnosis, cure, mitigation,
treatment, or |
24 | | prevention of disease in man or animals; (3) substances
(other |
25 | | than food) intended to affect the structure of any function of
|
26 | | the body of man or animals and (4) substances intended for use |
|
| | 10100HB2488sam003 | - 12 - | LRB101 07727 BMS 74688 a |
|
|
1 | | as a
component of any article specified in clause (1), (2), or |
2 | | (3) of this
subsection. It does not include devices or their |
3 | | components, parts, or
accessories.
|
4 | | (t-3) "Electronic health record" or "EHR" means an |
5 | | electronic record of health-related information on an |
6 | | individual that is created, gathered, managed, and consulted by |
7 | | authorized health care clinicians and staff. |
8 | | (t-3.5) "Electronic health record system" or "EHR system" |
9 | | means any computer-based system or combination of federally |
10 | | certified Health IT Modules (defined at 42 CFR 170.102 or its |
11 | | successor) used as a repository for electronic health records |
12 | | and accessed or updated by a prescriber or authorized surrogate |
13 | | in the ordinary course of his or her medical practice. For |
14 | | purposes of connecting to the Prescription Information Library |
15 | | maintained by the Bureau of Pharmacy and Clinical Support |
16 | | Systems or its successor, an EHR system may connect to the |
17 | | Prescription Information Library directly or through all or |
18 | | part of a computer program or system that is a federally |
19 | | certified Health IT Module maintained by a third party and used |
20 | | by the EHR system to secure access to the database. |
21 | | (t-4) "Emergency medical services personnel" has the |
22 | | meaning ascribed to it in the Emergency Medical Services (EMS) |
23 | | Systems Act. |
24 | | (t-5) "Euthanasia agency" means
an entity certified by the |
25 | | Department of Financial and Professional Regulation for the
|
26 | | purpose of animal euthanasia that holds an animal control |
|
| | 10100HB2488sam003 | - 13 - | LRB101 07727 BMS 74688 a |
|
|
1 | | facility license or
animal
shelter license under the Animal |
2 | | Welfare Act. A euthanasia agency is
authorized to purchase, |
3 | | store, possess, and utilize Schedule II nonnarcotic and
|
4 | | Schedule III nonnarcotic drugs for the sole purpose of animal |
5 | | euthanasia.
|
6 | | (t-10) "Euthanasia drugs" means Schedule II or Schedule III |
7 | | substances
(nonnarcotic controlled substances) that are used |
8 | | by a euthanasia agency for
the purpose of animal euthanasia.
|
9 | | (u) "Good faith" means the prescribing or dispensing of a |
10 | | controlled
substance by a practitioner in the regular course of |
11 | | professional
treatment to or for any person who is under his or |
12 | | her treatment for a
pathology or condition other than that |
13 | | individual's physical or
psychological dependence upon or |
14 | | addiction to a controlled substance,
except as provided herein: |
15 | | and application of the term to a pharmacist
shall mean the |
16 | | dispensing of a controlled substance pursuant to the
|
17 | | prescriber's order which in the professional judgment of the |
18 | | pharmacist
is lawful. The pharmacist shall be guided by |
19 | | accepted professional
standards including, but not limited to |
20 | | the following, in making the
judgment:
|
21 | | (1) lack of consistency of prescriber-patient |
22 | | relationship,
|
23 | | (2) frequency of prescriptions for same drug by one |
24 | | prescriber for
large numbers of patients,
|
25 | | (3) quantities beyond those normally prescribed,
|
26 | | (4) unusual dosages (recognizing that there may be |
|
| | 10100HB2488sam003 | - 14 - | LRB101 07727 BMS 74688 a |
|
|
1 | | clinical circumstances where more or less than the usual |
2 | | dose may be used legitimately),
|
3 | | (5) unusual geographic distances between patient, |
4 | | pharmacist and
prescriber,
|
5 | | (6) consistent prescribing of habit-forming drugs.
|
6 | | (u-0.5) "Hallucinogen" means a drug that causes markedly |
7 | | altered sensory perception leading to hallucinations of any |
8 | | type. |
9 | | (u-1) "Home infusion services" means services provided by a |
10 | | pharmacy in
compounding solutions for direct administration to |
11 | | a patient in a private
residence, long-term care facility, or |
12 | | hospice setting by means of parenteral,
intravenous, |
13 | | intramuscular, subcutaneous, or intraspinal infusion.
|
14 | | (u-5) "Illinois State Police" means the State
Police of the |
15 | | State of Illinois, or its successor agency. |
16 | | (v) "Immediate precursor" means a substance:
|
17 | | (1) which the Department has found to be and by rule |
18 | | designated as
being a principal compound used, or produced |
19 | | primarily for use, in the
manufacture of a controlled |
20 | | substance;
|
21 | | (2) which is an immediate chemical intermediary used or |
22 | | likely to
be used in the manufacture of such controlled |
23 | | substance; and
|
24 | | (3) the control of which is necessary to prevent, |
25 | | curtail or limit
the manufacture of such controlled |
26 | | substance.
|
|
| | 10100HB2488sam003 | - 15 - | LRB101 07727 BMS 74688 a |
|
|
1 | | (w) "Instructional activities" means the acts of teaching, |
2 | | educating
or instructing by practitioners using controlled |
3 | | substances within
educational facilities approved by the State |
4 | | Board of Education or
its successor agency.
|
5 | | (x) "Local authorities" means a duly organized State, |
6 | | County or
Municipal peace unit or police force.
|
7 | | (y) "Look-alike substance" means a substance, other than a |
8 | | controlled
substance which (1) by overall dosage unit |
9 | | appearance, including shape,
color, size, markings or lack |
10 | | thereof, taste, consistency, or any other
identifying physical |
11 | | characteristic of the substance, would lead a reasonable
person |
12 | | to believe that the substance is a controlled substance, or (2) |
13 | | is
expressly or impliedly represented to be a controlled |
14 | | substance or is
distributed under circumstances which would |
15 | | lead a reasonable person to
believe that the substance is a |
16 | | controlled substance. For the purpose of
determining whether |
17 | | the representations made or the circumstances of the
|
18 | | distribution would lead a reasonable person to believe the |
19 | | substance to be
a controlled substance under this clause (2) of |
20 | | subsection (y), the court or
other authority may consider the |
21 | | following factors in addition to any other
factor that may be |
22 | | relevant:
|
23 | | (a) statements made by the owner or person in control |
24 | | of the substance
concerning its nature, use or effect;
|
25 | | (b) statements made to the buyer or recipient that the |
26 | | substance may
be resold for profit;
|
|
| | 10100HB2488sam003 | - 16 - | LRB101 07727 BMS 74688 a |
|
|
1 | | (c) whether the substance is packaged in a manner |
2 | | normally used for the
illegal distribution of controlled |
3 | | substances;
|
4 | | (d) whether the distribution or attempted distribution |
5 | | included an
exchange of or demand for money or other |
6 | | property as consideration, and
whether the amount of the |
7 | | consideration was substantially greater than the
|
8 | | reasonable retail market value of the substance.
|
9 | | Clause (1) of this subsection (y) shall not apply to a |
10 | | noncontrolled
substance in its finished dosage form that was |
11 | | initially introduced into
commerce prior to the initial |
12 | | introduction into commerce of a controlled
substance in its |
13 | | finished dosage form which it may substantially resemble.
|
14 | | Nothing in this subsection (y) prohibits the dispensing or |
15 | | distributing
of noncontrolled substances by persons authorized |
16 | | to dispense and
distribute controlled substances under this |
17 | | Act, provided that such action
would be deemed to be carried |
18 | | out in good faith under subsection (u) if the
substances |
19 | | involved were controlled substances.
|
20 | | Nothing in this subsection (y) or in this Act prohibits the |
21 | | manufacture,
preparation, propagation, compounding, |
22 | | processing, packaging, advertising
or distribution of a drug or |
23 | | drugs by any person registered pursuant to
Section 510 of the |
24 | | Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
|
25 | | (y-1) "Mail-order pharmacy" means a pharmacy that is |
26 | | located in a state
of the United States that delivers, |
|
| | 10100HB2488sam003 | - 17 - | LRB101 07727 BMS 74688 a |
|
|
1 | | dispenses or
distributes, through the United States Postal |
2 | | Service or other common
carrier, to Illinois residents, any |
3 | | substance which requires a prescription.
|
4 | | (z) "Manufacture" means the production, preparation, |
5 | | propagation,
compounding, conversion or processing of a |
6 | | controlled substance other than methamphetamine, either
|
7 | | directly or indirectly, by extraction from substances of |
8 | | natural origin,
or independently by means of chemical |
9 | | synthesis, or by a combination of
extraction and chemical |
10 | | synthesis, and includes any packaging or
repackaging of the |
11 | | substance or labeling of its container, except that
this term |
12 | | does not include:
|
13 | | (1) by an ultimate user, the preparation or compounding |
14 | | of a
controlled substance for his or her own use; or
|
15 | | (2) by a practitioner, or his or her authorized agent |
16 | | under his or her
supervision, the preparation, |
17 | | compounding, packaging, or labeling of a
controlled |
18 | | substance:
|
19 | | (a) as an incident to his or her administering or |
20 | | dispensing of a
controlled substance in the course of |
21 | | his or her professional practice; or
|
22 | | (b) as an incident to lawful research, teaching or |
23 | | chemical
analysis and not for sale.
|
24 | | (z-1) (Blank).
|
25 | | (z-5) "Medication shopping" means the conduct prohibited |
26 | | under subsection (a) of Section 314.5 of this Act. |
|
| | 10100HB2488sam003 | - 18 - | LRB101 07727 BMS 74688 a |
|
|
1 | | (z-10) "Mid-level practitioner" means (i) a physician |
2 | | assistant who has been delegated authority to prescribe through |
3 | | a written delegation of authority by a physician licensed to |
4 | | practice medicine in all of its branches, in accordance with |
5 | | Section 7.5 of the Physician Assistant Practice Act of 1987, |
6 | | (ii) an advanced practice registered nurse who has been |
7 | | delegated authority to prescribe through a written delegation |
8 | | of authority by a physician licensed to practice medicine in |
9 | | all of its branches or by a podiatric physician, in accordance |
10 | | with Section 65-40 of the Nurse Practice Act, (iii) an advanced |
11 | | practice registered nurse certified as a nurse practitioner, |
12 | | nurse midwife, or clinical nurse specialist who has been |
13 | | granted authority to prescribe by a hospital affiliate in |
14 | | accordance with Section 65-45 of the Nurse Practice Act, (iv) |
15 | | an animal euthanasia agency, or (v) a prescribing psychologist. |
16 | | (aa) "Narcotic drug" means any of the following, whether |
17 | | produced
directly or indirectly by extraction from substances |
18 | | of vegetable origin,
or independently by means of chemical |
19 | | synthesis, or by a combination of
extraction and chemical |
20 | | synthesis:
|
21 | | (1) opium, opiates, derivatives of opium and opiates, |
22 | | including their isomers, esters, ethers, salts, and salts |
23 | | of isomers, esters, and ethers, whenever the existence of |
24 | | such isomers, esters, ethers, and salts is possible within |
25 | | the specific chemical designation; however the term |
26 | | "narcotic drug" does not include the isoquinoline |
|
| | 10100HB2488sam003 | - 19 - | LRB101 07727 BMS 74688 a |
|
|
1 | | alkaloids of opium;
|
2 | | (2) (blank);
|
3 | | (3) opium poppy and poppy straw;
|
4 | | (4) coca leaves, except coca leaves and extracts of |
5 | | coca leaves from which substantially all of the cocaine and |
6 | | ecgonine, and their isomers, derivatives and salts, have |
7 | | been removed;
|
8 | | (5) cocaine, its salts, optical and geometric isomers, |
9 | | and salts of isomers; |
10 | | (6) ecgonine, its derivatives, their salts, isomers, |
11 | | and salts of isomers; |
12 | | (7) any compound, mixture, or preparation which |
13 | | contains any quantity of any of the substances referred to |
14 | | in subparagraphs (1) through (6). |
15 | | (bb) "Nurse" means a registered nurse licensed under the
|
16 | | Nurse Practice Act.
|
17 | | (cc) (Blank).
|
18 | | (dd) "Opiate" means any substance having an addiction |
19 | | forming or
addiction sustaining liability similar to morphine |
20 | | or being capable of
conversion into a drug having addiction |
21 | | forming or addiction sustaining
liability.
|
22 | | (ee) "Opium poppy" means the plant of the species Papaver
|
23 | | somniferum L., except its seeds.
|
24 | | (ee-5) "Oral dosage" means a tablet, capsule, elixir, or |
25 | | solution or other liquid form of medication intended for |
26 | | administration by mouth, but the term does not include a form |
|
| | 10100HB2488sam003 | - 20 - | LRB101 07727 BMS 74688 a |
|
|
1 | | of medication intended for buccal, sublingual, or transmucosal |
2 | | administration. |
3 | | (ff) "Parole and Pardon Board" means the Parole and Pardon |
4 | | Board of
the State of Illinois or its successor agency.
|
5 | | (gg) "Person" means any individual, corporation, |
6 | | mail-order pharmacy,
government or governmental subdivision or |
7 | | agency, business trust, estate,
trust, partnership or |
8 | | association, or any other entity.
|
9 | | (hh) "Pharmacist" means any person who holds a license or |
10 | | certificate of
registration as a registered pharmacist, a local |
11 | | registered pharmacist
or a registered assistant pharmacist |
12 | | under the Pharmacy Practice Act.
|
13 | | (ii) "Pharmacy" means any store, ship or other place in |
14 | | which
pharmacy is authorized to be practiced under the Pharmacy |
15 | | Practice Act.
|
16 | | (ii-5) "Pharmacy shopping" means the conduct prohibited |
17 | | under subsection (b) of Section 314.5 of this Act. |
18 | | (ii-10) "Physician" (except when the context otherwise |
19 | | requires) means a person licensed to practice medicine in all |
20 | | of its branches. |
21 | | (jj) "Poppy straw" means all parts, except the seeds, of |
22 | | the opium
poppy, after mowing.
|
23 | | (kk) "Practitioner" means a physician licensed to practice |
24 | | medicine in all
its branches, dentist, optometrist, podiatric |
25 | | physician,
veterinarian, scientific investigator, pharmacist, |
26 | | physician assistant,
advanced practice registered nurse,
|
|
| | 10100HB2488sam003 | - 21 - | LRB101 07727 BMS 74688 a |
|
|
1 | | licensed practical
nurse, registered nurse, emergency medical |
2 | | services personnel, hospital, laboratory, or pharmacy, or |
3 | | other
person licensed, registered, or otherwise lawfully |
4 | | permitted by the
United States or this State to distribute, |
5 | | dispense, conduct research
with respect to, administer or use |
6 | | in teaching or chemical analysis, a
controlled substance in the |
7 | | course of professional practice or research.
|
8 | | (ll) "Pre-printed prescription" means a written |
9 | | prescription upon which
the designated drug has been indicated |
10 | | prior to the time of issuance; the term does not mean a written |
11 | | prescription that is individually generated by machine or |
12 | | computer in the prescriber's office.
|
13 | | (mm) "Prescriber" means a physician licensed to practice |
14 | | medicine in all
its branches, dentist, optometrist, |
15 | | prescribing psychologist licensed under Section 4.2 of the |
16 | | Clinical Psychologist Licensing Act with prescriptive |
17 | | authority delegated under Section 4.3 of the Clinical |
18 | | Psychologist Licensing Act, podiatric physician, or
|
19 | | veterinarian who issues a prescription, a physician assistant |
20 | | who
issues a
prescription for a controlled substance
in |
21 | | accordance
with Section 303.05, a written delegation, and a |
22 | | written collaborative agreement required under Section 7.5
of |
23 | | the
Physician Assistant Practice Act of 1987, an advanced |
24 | | practice registered
nurse with prescriptive authority |
25 | | delegated under Section 65-40 of the Nurse Practice Act and in |
26 | | accordance with Section 303.05, a written delegation,
and a |
|
| | 10100HB2488sam003 | - 22 - | LRB101 07727 BMS 74688 a |
|
|
1 | | written
collaborative agreement under Section 65-35 of the |
2 | | Nurse Practice Act, an advanced practice registered nurse |
3 | | certified as a nurse practitioner, nurse midwife, or clinical |
4 | | nurse specialist who has been granted authority to prescribe by |
5 | | a hospital affiliate in accordance with Section 65-45 of the |
6 | | Nurse Practice Act and in accordance with Section 303.05, or an |
7 | | advanced practice registered nurse certified as a nurse |
8 | | practitioner, nurse midwife, or clinical nurse specialist who |
9 | | has full practice authority pursuant to Section 65-43 of the |
10 | | Nurse Practice Act.
|
11 | | (nn) "Prescription" means a written, facsimile, or oral |
12 | | order, or an electronic order that complies with applicable |
13 | | federal requirements,
of
a physician licensed to practice |
14 | | medicine in all its branches,
dentist, podiatric physician or |
15 | | veterinarian for any controlled
substance, of an optometrist in |
16 | | accordance with Section 15.1 of the Illinois Optometric |
17 | | Practice Act of 1987, of a prescribing psychologist licensed |
18 | | under Section 4.2 of the Clinical Psychologist Licensing Act |
19 | | with prescriptive authority delegated under Section 4.3 of the |
20 | | Clinical Psychologist Licensing Act, of a physician assistant |
21 | | for a
controlled substance
in accordance with Section 303.05, a |
22 | | written delegation, and a written collaborative agreement |
23 | | required under
Section 7.5 of the
Physician Assistant Practice |
24 | | Act of 1987, of an advanced practice registered
nurse with |
25 | | prescriptive authority delegated under Section 65-40 of the |
26 | | Nurse Practice Act who issues a prescription for a
controlled |
|
| | 10100HB2488sam003 | - 23 - | LRB101 07727 BMS 74688 a |
|
|
1 | | substance in accordance
with
Section 303.05, a written |
2 | | delegation, and a written collaborative agreement under |
3 | | Section 65-35 of the Nurse Practice Act, of an advanced |
4 | | practice registered nurse certified as a nurse practitioner, |
5 | | nurse midwife, or clinical nurse specialist who has been |
6 | | granted authority to prescribe by a hospital affiliate in |
7 | | accordance with Section 65-45 of the Nurse Practice Act and in |
8 | | accordance with Section 303.05 when required by law, or of an |
9 | | advanced practice registered nurse certified as a nurse |
10 | | practitioner, nurse midwife, or clinical nurse specialist who |
11 | | has full practice authority pursuant to Section 65-43 of the |
12 | | Nurse Practice Act.
|
13 | | (nn-5) "Prescription Information Library" (PIL) means an |
14 | | electronic library that contains reported controlled substance |
15 | | data. |
16 | | (nn-10) "Prescription Monitoring Program" (PMP) means the |
17 | | entity that collects, tracks, and stores reported data on |
18 | | controlled substances and select drugs pursuant to Section 316. |
19 | | (oo) "Production" or "produce" means manufacture, |
20 | | planting,
cultivating, growing, or harvesting of a controlled |
21 | | substance other than methamphetamine.
|
22 | | (pp) "Registrant" means every person who is required to |
23 | | register
under Section 302 of this Act.
|
24 | | (qq) "Registry number" means the number assigned to each |
25 | | person
authorized to handle controlled substances under the |
26 | | laws of the United
States and of this State.
|
|
| | 10100HB2488sam003 | - 24 - | LRB101 07727 BMS 74688 a |
|
|
1 | | (qq-5) "Secretary" means, as the context requires, either |
2 | | the Secretary of the Department or the Secretary of the |
3 | | Department of Financial and Professional Regulation, and the |
4 | | Secretary's designated agents. |
5 | | (rr) "State" includes the State of Illinois and any state, |
6 | | district,
commonwealth, territory, insular possession thereof, |
7 | | and any area
subject to the legal authority of the United |
8 | | States of America.
|
9 | | (rr-5) "Stimulant" means any drug that (i) causes an |
10 | | overall excitation of central nervous system functions, (ii) |
11 | | causes impaired consciousness and awareness, and (iii) can be |
12 | | habit-forming or lead to a substance abuse problem, including |
13 | | but not limited to amphetamines and their analogs, |
14 | | methylphenidate and its analogs, cocaine, and phencyclidine |
15 | | and its analogs. |
16 | | (rr-10) "Synthetic drug" includes, but is not limited to, |
17 | | any synthetic cannabinoids or piperazines or any synthetic |
18 | | cathinones as provided for in Schedule I. |
19 | | (ss) "Ultimate user" means a person who lawfully possesses |
20 | | a
controlled substance for his or her own use or for the use of |
21 | | a member of his or her
household or for administering to an |
22 | | animal owned by him or her or by a member
of his or her |
23 | | household.
|
24 | | (Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15; |
25 | | 99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16; |
26 | | 100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff. |
|
| | 10100HB2488sam003 | - 25 - | LRB101 07727 BMS 74688 a |
|
|
1 | | 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. 8-14-18 .)
|
2 | | (720 ILCS 570/220 new) |
3 | | Sec. 220. Electronic health record systems. The Bureau of |
4 | | Pharmacy and Clinical Support Systems shall establish a form to |
5 | | allow EHR systems to certify the identity of a third party that |
6 | | will provide access to the Prescription Information Library for |
7 | | the EHR system using all or part of a computer program or |
8 | | system that is a federally certified Health IT Module for the |
9 | | EHR system. Before the Health IT Module is permitted to connect |
10 | | to the Prescription Information Library, it must enter into a |
11 | | business associate agreement with the EHR system that requires |
12 | | the Health IT Module to agree to adhere to all requirements |
13 | | imposed on the EHR system by the laws of this State, including |
14 | | data privacy and security obligations that the Bureau otherwise |
15 | | imposes on EHR systems. ".
|